Committees of the Board
There are a number of Sub Committees of the Board
The Audit Committee provides oversight of the organisation’s finances. The Nominations & Governance Committee oversees Board membership and governance.
The Clinical Executive Committee is responsible for discussing, agreeing and making recommendations to the Board on important issues related to clinical and operational aspects of cancer care delivery relevant to cancer clinical trial execution and has the authority to represent and make recommendations to the Board on behalf of the Cancer Trials Research Units.
The Patient Consultants Committee (PCC) brings together people affected by cancer to influence cancer trials and contribute a consumer perspective to trial activity in Ireland. The work of the PCC also includes networking and planning. The PCC will provide a visible focus of Personal and Public Involvement (PPI) in cancer trials in Ireland.
The Scientific Management Group (SMG) is responsible for the planning and development of scientific research priorities and the resourcing of these priorities within the allocated Cancer Trials Ireland funding. This involves setting the strategy in terms of under-served disease areas, ratio of academic versus industry studies, and the balance of studies across disease areas. The SMG reports to the Board through the Clinical Executive Committee.
The Disease Specific Sub Groups (DSSGs). There is a DSSG representing each relevant disease area. Each group is responsible for discussing potential new studies and/or collaborations. Once a study has been approved by a DSSG and has undergone peer review (if applicable), the study is submitted to the SMG for approval.
The External Scientific Advisory Review Board. Consultations are currently underway in relation to the role of this Board to clarify and maximise its input.